ArticleBMC neurology2025
Integrative analysis of mRNA and LncRNA profiles from small extracellular vesicles identifies apoptosis-related biomarkers in patients with Parkinson's disease after rehabilitation.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundIncreasing evidence has highlighted the crucial role of long noncoding RNAs (lncRNAs) and messenger RNAs (mRNAs) in the development and progression of Parkinson’s disease (PD). Investigating which lncRNA and mRNA biomarkers are associated with PD rehabilitation is valuable.
methodsSix patients with PD (PWP, Hoehn & Yahr stages 1.5–2.5) and age- and sex-matched healthy controls (HCs) were recruited. Total RNA was extracted from extracellular vesicles (EVs) from peripheral blood samples collected before and after 14 days of rehabilitation in the hospital. Differentially expressed mRNAs (DEmRNAs) and differentially expressed lncRNAs (DElncRNAs) were identified via next-generation sequencing (NGS), and a coexpression network was constructed.
resultsOverall, 3038 DEmRNAs (2337 upregulated/701 downregulated) and 1723 DElncRNAs (1278 upregulated/445 downregulated) were identified between prerehabilitation (prerehab) PWPs and HCs, whereas 3117 DEmRNAs (2490 upregulated/629 downregulated) and 1931 DElncRNAs (1561 upregulated/370 downregulated) were identified between postrehabilitation (postrehab) PWPs and HCs. Moreover, 1662 DEmRNAs (606 upregulated/1056 downregulated) and 1729 DElncRNAs (593 upregulated/1136 downregulated) were identified between prerehab PWPs and postrehab PWPs. Four DEmRNAs and 19 DElncRNAs were found in the blood EVs of both pre- and postrehab PWPs. GO and KEGG enrichment analyses revealed significant enrichment of the DEGs associated with the apoptotic process, mitogen-activated protein kinase (MAPK) signaling pathway, and Wnt signaling pathway. Coexpression network analysis revealed one DEmRNA (ENSG00000168646, AXIN2) and one positively related DElncRNA (ENST00000577329). The expression of the DEGs was validated in human samples via quantitative reverse transcription polymerase chain reaction (qRT‒PCR).
conclusionsThese findings suggest that the apoptotic pathway-related biomarker AXIN2 may be involved in PD rehabilitation, which should be further confirmed in clinical evaluations after PD rehabilitation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.